Association of <i>BRCA1</i> and <i>BRCA2</i> mutations with overall survival (A) and Progression-free survival (B) in ovarian cancer.

<p>Association of <i>BRCA1</i> and <i>BRCA2</i> mutations with overall survival (A) and Progression-free survival (B) in ovarian cancer.</p

Association of the genomic instability score with HR-deficiency and platinum-response in ovarian cancer.

<p>(<b>A</b>) The distribution of score in <i>BRCA1</i> hyper-methylated patients is significantly higher than that in <i>BRCA</i> wild-type patients. (<b>B</b>) The distribution of score in HR-deficient patients (including <i>EMSY</i> amplification cases, and <i>PTEN</i>, Fanconi Anemia genes, <i>RAD</i> genes, <i>ATM</i>, <i>ATR</i> and <i>CHEK1/2</i> deficient cases) is significantly higher than that in other <i>BRCA</i> wild-type patients. (<b>C</b>) Association of the score with complete response (CR). The scores of all patients (n = 325) were divided into 12 equal intervals. The percentage of patients achieving a CR (according to the Response Evaluation Criteria in Solid Tumors) was calculated for patients in each interval and was plotted against each scoring interval in increasing order. Patients in high scoring interval show increasing likelihood of achieving CR. The dashed line represents linear regression line through the data points. (<b>D</b>) Same as (<b>C</b>) but calculating for platinum-status. 133 platinum-sensitive patients and 62 platinum-resistant patients were analyzed.</p

Clinicopathologic characteristics with different BRCA1/2 status.

<p>For categorical data (Tumor stage and grade, residual tumor size, response to chemotherapy therapy and platinum status), the Fisher exact test was used to calculate P value in <i>R</i>; for continuous variable such as age, the Wilcoxon rank sum test was used in <i>R</i>. Patients with debulking status “no macroscopic disease” are labeled as 0 cm in residual tumor size. Number (NO.) depicts the corresponding number of patients in each category. Missing values are excluded from the test analyses. BRCA wild-type cases do not include the BRCA1 methylation cases.</p><p>Clinicopathologic characteristics with different BRCA1/2 status.</p

Cox proportional hazard model using relevant pretreatment factors for patients with different BRCA1/2 mutation status.

<p>Abbreviations: High/Low BRCA, BRCA mutation cases in high/low level group of mutations, CNCs or scores; HR, hazard ratio; CI, confidence interval; Debulking, residual tumor size.</p><p>Two-sided <i>P</i> values were calculated using Cox regression model adjusting for all the variables in the table.</p><p>Patients with debulking status “no macroscopic disease” are labeled as 0 cm.</p><p>Cox proportional hazard model using relevant pretreatment factors for patients with different BRCA1/2 mutation status.</p

Association of genomic instability with <i>BRCA1/2</i> mutations and survival in ovarian cancer.

<p>(<b>A</b>) Both <i>BRCA1</i> and <i>BRCA2</i> mutated tumors show elevated level genome mutations. High mutation group of <i>BRCA1/2</i> mutated ovarian cancer patients shows significantly improved survival than wild-type patients, whereas low mutation group of <i>BRCA1/2</i> mutated patients shows nonsignificant difference compared with wild-type patients. (<b>B</b>) Both <i>BRCA1</i> and <i>BRCA2</i> mutated tumors show increased copy number changes. High CNCs group of <i>BRCA1/2</i> mutated ovarian cancer patients shows significantly improved survival than wild-type patients, whereas low CNCs group shows nonsignificant difference compared with wild-type patients. (<b>C</b>) Both <i>BRCA1</i> and <i>BRCA2</i> mutated patients show increased genomic instability score, with <i>BRCA2</i> mutated patients show higher score distribution than <i>BRCA1</i> mutated patients. High scoring group of <i>BRCA1/2</i> mutated patients shows significantly improved survival than wild-type patients, whereas low scoring group shows nonsignificant difference compared with wild-type patients.</p

Association of high vs low scoring subgroup with clinical characteristics.

<p>Association of high vs low scoring subgroup with clinical characteristics.</p

Experimental and Numerical Studies on a One-Step Method for the Production of Mg in the Silicothermic Reduction Process

In this paper, a new efficient one-step technical method was first developed for the production of magnesium in the industry. The one-step method could combine the two processes of dolomite decomposition and magnesium reduction in the magnesium reduction retort. Thus, the high-temperature carbon dioxide produced by the dolomite decomposition process could be collected in a timely manner instead of being emitted into the atmosphere, and excessive heat loss caused by the two separate processes also could be almost completely avoided. This paper presents an experimental study on the intrinsic chemical kinetics mechanisms of this new efficient one-step technology. By applying each of the most likely solid-state kinetic models, the kinetic parameters of the two reactions that reacted during the dolomite decomposition stage and magnesium reduction stage were evaluated, and the kinetic models that best verify the experimental data were attempted. For the dolomite decomposition stage of the one-step technology, the equation of the chemical kinetic model can be represented by α²/2 = <i>k</i>_D1τ in the temperature range of 1173–1473 K, and the apparent activation energy was determined to be 160.6 kJ mol^–1. For the magnesium reduction stage of the one-step technology, the surface reaction chemical kinetic model 1 – (1 – β)^1/3= <i>k</i>_Sτ described very satisfactorily the experimental values for the different reduction temperature. Then, a one-step model incorporating the chemical reaction kinetics of the dolomite decomposition stage and the magnesium reduction stage and heat conduction was first developed. The simulations of the impact of heating temperature on the dolomite decomposition stage and magnesium reduction stage were carried out in the reduction retorts of the furnace utilizing this model. The distribution of dolomite decomposition extent in the retorts, the total extent of dolomite decomposition with time, the distribution of magnesium reduction extent in the retorts, and the total extent of magnesium reduction with time were studied in detail. The analysis showed that the one-step technology is effective in not only reducing the cycle time of dolomite decomposition stage and magnesium reduction stage but also saving energy

Biological parameters of bivalves used in the experimental systems.

<p>Biological parameters of bivalves used in the experimental systems.</p

Biological filter-removing rates of suspended particles in aquaculture wastewater by experimental bivalves.

<p>Sedimentation rates (mg•d⁻¹): the sedimentation rate of suspended solids in the FT system; Ratios of sedimentation rates: ratios of the sedimentation rate of suspended solids in a bivalve treatment to that in the control (without bivalves); Percentage of TSS reduced (%): percentage of TSS reduced in the outflow water in oyster or mussel treatment, compared with control treatment without bivalves. Values are given as means±SD. Values with different superscripted letters in the same column are significantly different from each other (<i>P</i><0.05).</p><p>Biological filter-removing rates of suspended particles in aquaculture wastewater by experimental bivalves.</p

Schematic diagram of individual experimental biotanks.

<p>Each biotank measured 75×50×50 cm in size. A, Flowmeter; B, Control valve; C, Lantern net deployed in a biotank for bivalve culture.</p